Statement Of Cash Flows [Abstract]

Pharming Group N.V. - Filing #5829944

Concept 2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for finance income
6,843,000 USD
3,663,000 USD
Cash flows from (used in) operations before changes in working capital
18,660,000 USD
2,569,000 USD
Increase (decrease) in working capital
10,072,000 USD
16,961,000 USD
Adjustments for decrease (increase) in trade and other receivables
6,783,000 USD
18,539,000 USD
Adjustments for increase (decrease) in trade and other payables
2,769,000 USD
16,228,000 USD
Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss
16,070,000 USD
15,925,000 USD
Cash flows from (used in) investing activities [abstract]
Cash flows from (used in) decrease (increase) in restricted cash and cash equivalents
17,000 USD
216,000 USD
Purchase of financial instruments, classified as investing activities
284,314,000 USD
382,014,000 USD
Proceeds from sales or maturity of financial instruments, classified as investing activities
314,630,000 USD
232,811,000 USD
Cash flows from (used in) financing activities [abstract]
Proceeds from issue of bonds, notes and debentures
104,539,000 USD
USD
Repayments of bonds, notes and debentures
134,924,000 USD
USD

Talk to a Data Expert

Have a question? We'll get back to you promptly.